Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly has agreed to buy Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders, in order to acquire insomnia drug HY10275.
Subscribe to our email newsletter
The transaction has received approval from Hypnion stockholders and is expected to close near the end of the first quarter of 2007, subject to regulatory clearance. Financial terms of the deal were not disclosed.
“The acquisition of Hypnion provides Lilly with a broader and more substantive presence in the area of sleep disorder research,” said Steven Paul, executive vice president of science and technology for Lilly.
“Hypnion has leveraged its expertise in this area to develop both innovative technologies and molecules, including the promising insomnia compound HY10275. We are excited to bring this expertise to Lilly and continue the efforts to discover better treatments for patients struggling with insomnia and other sleep disorders.”
In January, Hypnion announced that its compound HY10275 met the primary and secondary endpoints in the company's initial phase II clinical trial at doses of 1mg and 3mg in adults with transient insomnia.